Together, these data consistently indicate that LKB1 inactivation in NSCLC specimens is associated with low PD-L1 expression and with lower chances to benefit from chemotherapy and/or immunotherapy in the advanced disease setting. The gene discussed is STK11; the disease is non-small cell lung carcinoma.